Oncology Hematology Areas of Interest

Areas of Interest for additional hematology compounds are coming soon.

Submissions are aligned to quarterly portal cut‑offs, with applications reviewed by intake cycle.

Brand or Substance	Submissions being Considered	Areas of Interest	Out of Scope
CARVYKTI® (ciltacabtagene autoleucel)	Commercial supply only	Adverse event (e.g. NTX, colitis, SPM, prolonged cytopenia, infections) management/mitigation measures Registries Effectiveness of potential mitigation measures Mechanism of potential mitigation measures Real world evidence for cilta-cel in early lines RRMM (effectiveness, safety, special populations etc.) Select MoA and biomarkers of efficacy and safety - correlates of response/resistance as well as toxicity Sequencing and washout strategies not involving other J&J assets Bridging and holding therapies not involving other J&J assets	Interventional studies requiring cilta-cel supply Research proposals outside of myeloma/plasma cell disorders Duplication of ongoing, planned, published, or collaborative studies MAF study supportive of any other CAR-T Head-to-head studies with competitors